Finding 1224288 (2025-001)

Material Weakness Repeat Finding
Requirement
AB
Questioned Costs
-
Year
2025
Accepted
2026-07-21
Audit: 407580
Organization: HEALTHX PARTNERS INCORPORATED (DC)
Auditor: BDO

AI Summary

  • Core Issue: HealthXP failed to effectively review and approve expenditures, leading to an unallowable business-class airfare expense of $5,930.
  • Impacted Requirements: This finding violates federal regulations under §200.303 and §200.475 regarding internal controls and allowable travel costs.
  • Recommended Follow-Up: HealthXP should enhance training for staff to ensure compliance with expenditure review policies and procedures.

Finding Text

Internal Control over Compliance and Compliance with Activities Allowed or Unallowed and Allowable Costs and Cost Principles Identification of the Federal Programs: As this is an indirect cost allocation finding, all Population Services International (PSI) awards on the SEFA are impacted. See Schedule of Findings and Questioned Costs for table. Criteria or Specific Requirement: In accordance with §200.303 Internal Controls, a non-federal entity must (a) establish and maintain effective internal control over the federal award that provides reasonable assurance that the non-federal entity is managing the federal award in compliance with federal statutes, regulations, and the terms and conditions of the federal award. Additionally, §200.475(e) Travel costs, states that airfare costs in excess of the basic least expensive unrestricted accommodations class offered by commercial airlines are unallowable except when such accommodations would: (i) require circuitous routing; (ii) require travel during unreasonable hours; (iii) excessively prolong travel; (iv) result in additional costs that would offset the transportation savings; or (v) offer accommodations not reasonably adequate for the traveler's medical needs. The recipient or subrecipient must justify and document these conditions on a case-by-case basis for the use of first-class or business-class airfare to be allowable in such cases. Condition: HealthXP has documented policies and internal controls over allowability of expenditures incurred. However, as identified below, the review and approval process did not operate effectively. During our testing of the indirect cost pool, we identified one unallowable unapproved expense out of 25 samples tested. The exception involved a business-class airfare totaling $5,930, which does not comply with 2 CFR §200.475, Travel costs. Questioned Costs: Known questioned costs associated with the business class airfare totaled $5,930. Context: This is a condition identified per review of HealthXP’s compliance with allowability and allocability provisions of the Uniform Guidance. The prevalence of this finding is detailed in the condition section above. Samples were selected using a non-statistical method. Cause: HealthXP has documented expenditure policies and procedures regarding the review and approval of expenditures incurred. However, as identified above, the review and approval process for the sample identified above did not operate effectively. Effect: Because this unallowable amount was included in the indirect cost pool allocated across all federal programs, this noncompliance affects all PSI federal awards listed on HealthXP’s Schedule of Expenditures of Federal Awards for the year ended December 31, 2025. Repeat Finding: This is not a repeat finding. Recommendation: We recommend HealthXP adhere to documented policies and procedures regarding review and approval of expenditures. Views of Responsible Officials: HealthXP management agrees with the finding and recommendations set forth within and will provide additional training to staff members to ensure compliance with established policies and procedures. Refer to management’s corrective action plan for additional information.

Corrective Action Plan

Internal Control over Compliance and Compliance with Activities Allowed or Unallowed and Allowable Costs and Cost Principles Contact: Katie Queen Dossinger Title: Chief Operating Officer Phone Number: 202-785-0072 Estimated Completion Date: Ongoing Corrective Action The results of the 2025 audit will be shared with appropriate staff and reiterated in training to ensure that adequate attention and guidance is provided on recording expenses within the correct accounting period. HealthXP delivers in person training to its global finance and program staff and will continue to offer training during 2026 to address such issues.

Categories

Allowable Costs / Cost Principles Reporting

Other Findings in this Audit

  • 1224236 2025-001
    Material Weakness Repeat
  • 1224237 2025-001
    Material Weakness Repeat
  • 1224238 2025-001
    Material Weakness Repeat
  • 1224239 2025-001
    Material Weakness Repeat
  • 1224240 2025-001
    Material Weakness Repeat
  • 1224241 2025-001
    Material Weakness Repeat
  • 1224242 2025-001
    Material Weakness Repeat
  • 1224243 2025-001
    Material Weakness Repeat
  • 1224244 2025-001
    Material Weakness Repeat
  • 1224245 2025-001
    Material Weakness Repeat
  • 1224246 2025-005
    Material Weakness Repeat
  • 1224247 2025-001
    Material Weakness Repeat
  • 1224248 2025-001
    Material Weakness Repeat
  • 1224249 2025-001
    Material Weakness Repeat
  • 1224250 2025-001
    Material Weakness Repeat
  • 1224251 2025-001
    Material Weakness Repeat
  • 1224252 2025-001
    Material Weakness Repeat
  • 1224253 2025-001
    Material Weakness Repeat
  • 1224254 2025-001
    Material Weakness Repeat
  • 1224255 2025-001
    Material Weakness Repeat
  • 1224256 2025-001
    Material Weakness Repeat
  • 1224257 2025-001
    Material Weakness Repeat
  • 1224258 2025-001
    Material Weakness Repeat
  • 1224259 2025-001
    Material Weakness Repeat
  • 1224260 2025-001
    Material Weakness Repeat
  • 1224261 2025-001
    Material Weakness Repeat
  • 1224262 2025-001
    Material Weakness Repeat
  • 1224263 2025-001
    Material Weakness Repeat
  • 1224264 2025-001
    Material Weakness Repeat
  • 1224265 2025-001
    Material Weakness Repeat
  • 1224266 2025-001
    Material Weakness Repeat
  • 1224267 2025-001
    Material Weakness Repeat
  • 1224268 2025-001
    Material Weakness Repeat
  • 1224269 2025-001
    Material Weakness Repeat
  • 1224270 2025-001
    Material Weakness Repeat
  • 1224271 2025-001
    Material Weakness Repeat
  • 1224272 2025-001
    Material Weakness Repeat
  • 1224273 2025-004
    Material Weakness Repeat
  • 1224274 2025-001
    Material Weakness Repeat
  • 1224275 2025-001
    Material Weakness Repeat
  • 1224276 2025-001
    Material Weakness Repeat
  • 1224277 2025-001
    Material Weakness Repeat
  • 1224278 2025-001
    Material Weakness Repeat
  • 1224279 2025-001
    Material Weakness Repeat
  • 1224280 2025-001
    Material Weakness Repeat
  • 1224281 2025-001
    Material Weakness Repeat
  • 1224282 2025-001
    Material Weakness Repeat
  • 1224283 2025-001
    Material Weakness Repeat
  • 1224284 2025-001
    Material Weakness Repeat
  • 1224285 2025-001
    Material Weakness Repeat
  • 1224286 2025-001
    Material Weakness Repeat
  • 1224287 2025-001
    Material Weakness Repeat
  • 1224289 2025-004
    Material Weakness Repeat
  • 1224290 2025-005
    Material Weakness Repeat
  • 1224291 2025-003
    Material Weakness Repeat
  • 1224292 2025-002
    Material Weakness Repeat
  • 1224293 2025-003
    Material Weakness Repeat
  • 1224294 2025-003
    Material Weakness Repeat
  • 1224295 2025-003
    Material Weakness Repeat
  • 1224296 2025-003
    Material Weakness Repeat
  • 1224297 2025-003
    Material Weakness Repeat
  • 1224298 2025-003
    Material Weakness Repeat
  • 1224299 2025-005
    Material Weakness Repeat

Programs in Audit

ALN Program Name Expenditures
98.U00 USAID/Tanzania's Client-Centered Health Program - HIV and Tuberculosis Northern (C3HP-NIV&TB Northern) $15.41M
98.U00 Global Health Supply Chain (GSHC) - Procurement and Supply Management (PSM) $3.18M
12.350 DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM $2.64M
98.U00 Donated Commodities $2.17M
98.U00 Southern Africa's Attain & Sustain 95-95-95, Present New Infections and Reach All Populations for Epidemic Control (ASPIRE) $1.03M
93.067 GLOBAL AIDS $1.01M
98.001 USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS $894,682
12.420 MILITARY MEDICAL RESEARCH AND DEVELOPMENT $203,175
98.U00 PMI Prevention of Malaria Through Vector Control $190,245
98.U00 USAID Western Kenya Sanitation (WKSP) $146,407
98.U00 Ethiopia Urban Water, Sanitation and Hygiene (WASH) Activity $123,146
98.U00 USAID West Africa Municipal Wash (MuniWASH) $66,273
98.U00 USAID WASH Services $60,267
98.U00 WCA_USAID_Transform IDIQ $1,285